Grade 3 or higher hypertension (28.4% vs. 5.2%) and proteinuria (1.9% vs. 0%), two main AEs of anti-VEGF therapy, were more frequent in patients receiving gefitinib plus anlotinib than patients receiving gefitinib plus placebo and are largely consistent with those of anlotinib therapy for other tumors.46 The rate of grade 3 or higher hypertension and proteinuria is lower than that (hypertension 37–60% and proteinuria 7–8%) reported for erlotinib plus bevacizumab in other trials.38,47–49 Overall, gefitinib plus anlotinib had a manageable toxicity profile in advanced NSCLC patients. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.